<DOC>
	<DOCNO>NCT00403026</DOCNO>
	<brief_summary>Bevacizumab anti-VEGF agent use approve use metastatic colorectal carcinoma ( FDA Approved ) . This study analyze safety efficacy off-label Intravitreal Injection bevacizumab ( Avastin ) CNVM , Macular oedema due diabetic retinopathy , vascular occlusion retinal disorder .</brief_summary>
	<brief_title>Intravitreal Bevacizumab Retinal Disorders</brief_title>
	<detailed_description>Purpose : To study efficacy safety invitreal injection bevacizumab ( avastin ) follow condition . - Age relate macular degeneration Juxtafoveal Subfoveal CNVM : Recurrent CNVM follow PDT TTT IVTA . Patient could afford PDT , Macugen Lucentis FDA approve . - Myopic CNVM , Idiopathic CNVM , Inflammatory CNVM condition associate CNVM . - Refractory macular oedema due vein occlusion , Pseudophakia , Clinically significant macular oedema ( CSME ) etc . affect vision respond adequately usual treatment method . - Proliferative diabetic retinopathy , non-resolving vitreous haemorrhage PDR - Informed consent take patient , base guideline OMIC ( Ophthalmic mutual insurance company ) Avastin : Risk management recommendation consent form . American Academy ophthalmology-Risk management recommendation off-label , Intravitreal use Avastin . Included indication , exclusion criterion , possible complication off-label status drug . Best correct visual acuity , Fundus Photography , anterior segment examination , Optical coherence tomography select patient Electrophysiology , VEP Fundus fluorescein angiography do accord surgeon discretion . All patient examine day 1 , 1st week subsequently depend surgeon discretion test perform follow ups . During follow best-corrected visual acuity , anterior posterior segment examination . Fundus photography , Intraocular pressure OCT repeat select patient FFA , ERG , VEP do , physician follow do . Preparation Drug : Bevacizumab Avastin ( Avastin ) come sterile vial ( 100 mg 4 ml ) preservative free ensure safety vial injection within day . Injections give 30 gauge needle , tuberculin syrinx single use . 0.05ml contain 1.25 mg drug give intravitreally aseptic precaution topical anaesthesia , suggest Flynn , Harry w.and scott , Ingrid u . –Evolving guideline intravitreous injection . Following injection topical antibiotic give 1 week . Design : Prospective interventional non randomise case series . Informed consent process Informed consent take English patient explain local language treat surgeon . The Food Drug Administration approve Avastin treatment metastatic Colorectal cancer . It first humanize Anti-VEGF antibody , prevents angiogenesis . Since drug FDA approve off-label drug use Intravitreal usage . For purpose patient well-informed product , base , use firm scientific method sound medical evidence , maintain record use effect . Ophthalmologists use Avastin “ off-label ” treat AMD similar condition since research indicate VEGF one cause growth abnormal vessel cause condition . All patient inform “ off-label ” status , FDA approve . Similar kenalog , FDA approve off-label drug use Intravitreal injection treat eye condition .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Age relate macular degeneration Juxtafoveal Subfoveal CNVM : Recurrent CNVM follow PDT TTT IVTA . Patient could afford PDT , Macugen Lucentis FDA approve . Myopic CNVM , Idiopathic CNVM , Inflammatory CNVM condition associate CNVM . Refractory macular oedema due vein occlusion , Pseudophakia , Clinically significant macular oedema ( CSME ) etc . affect vision respond adequately usual treatment method . Proliferative diabetic retinopathy , nonresolving vitreous haemorrhage PDR . Patients poor compliance Patients uncontrolled diabetes hypertension medical condition increase risk complication like recent history Stroke myocardial infraction ( &lt; one year ) . ( Physician clearance obtain patient ) . Patients undergone major surgery 28 day , exclude study also suspend prior elective surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>Bevacizumab ( Avastin )</keyword>
	<keyword>Intravitreal injection</keyword>
	<keyword>VEGF</keyword>
	<keyword>CRVO</keyword>
	<keyword>BRVO</keyword>
	<keyword>PDR</keyword>
	<keyword>CNVM</keyword>
</DOC>